Teen pregnancy in the setting of familial dilated cardiomyopathy: a case report

Joshua S. George* and Jeffrey Johnson

Abstract

Background: Women with pre-existing forms of familial cardiomyopathy are at increased risk for morbidity and mortality due to hemodynamic changes of pregnancy. There is a lack of consensus about the management and care for these patients given the rarity of this condition. This case represents possibly the youngest pregnant familial dilated cardiomyopathy patient to deliver and the youngest patient to be fitted for a wearable cardiac defibrillator in the postpartum period.

Case Presentation: A 14-year-old gravida 1 with familial dilated cardiomyopathy presented late for prenatal care at 38 weeks, which precluded typical care plans including baseline and serial echocardiograms, medication management, and routine prenatal care. An echocardiogram showed severely decreased left ventricular systolic function compared to studies from one year prior. Three days later the patient presented in labor and had a spontaneous vaginal delivery complicated by postpartum hemorrhage. Her postpartum course was notable for persistence of decreased cardiac function testing and placement of a wearable cardiac defibrillator for prevention against life-threatening arrhythmias.

Conclusion: This case report adds to the literature on pregnancy complicated by familial dilated cardiomyopathy and describes management best practices and considerations during the antepartum, intrapartum, and postpartum periods.

Keywords: Familial Dilated Cardiomyopathy, Teen Pregnancy, Prenatal Care

Background

Pregnancy and the postpartum period are a time of hemodynamic instability. These changes can be consequential for the morbidity and mortality of women with pre-existing cardiomyopathy (CDM), a subset of which is familial dilated cardiomyopathy (FDC) [1, 2]. Pregnancy has been shown to worsen cardiac function and outcomes in patients with CDM, especially in those with left ventricular ejection fraction (LVEF) < 40% [3, 4]. Pregnancy-induced hypervolemia results in increased end-diastolic dimension and cardiac decompensation. Another contributing factor is the discontinuation of typical management methods for CDM such as aldosterone antagonists and angiotensin converting enzyme inhibitors (ACEI) both of which are recommended to be stopped prior to conception [5]. Other hypothesized etiologies include immune system activation by fetal micro-chimerism and by genetic predispositions that are exacerbated by hemodynamic stress [6]. We present a case of the youngest reported patient with FDC to successfully deliver and describe management considerations based on existing literature.

Case presentation

A 14-year-old gravida 1 with familial dilated cardiomyopathy initially diagnosed at 15 months presented extremely late to prenatal care at 38 weeks gestation.

*Correspondence: jsgeorge@med.wayne.edu
Department of Obstetrics and Gynecology, Wayne State University, Detroit, USA
Medical history
The patient was diagnosed at 15 months with dilated cardiomyopathy, small ventricular septal defect (2 mm), and mild mitral regurgitation. Echocardiogram showed mildly increased left ventricular end diastolic diameter at 36 mm and "mildly decreased" ejection fraction (no numerical value was given). The patient was started on enalapril 5 mg twice daily and followed with serial echocardiograms.

The patient had routine clinical evaluation and echocardiograms twice yearly and remained asymptomatic until loss of follow up at age 13. At this time, which was about one year prior to her pregnancy, the patient had exercise stress testing which was normal. Cardiology documentation specified that the patient should not participate in competitive athletics.

Family history
The patient's maternal uncle was diagnosed with CDM at age 30 and died at age 39. The patient's mother was diagnosed with CDM and atrial fibrillation and underwent ICD placement at age 37. She had declined genetic testing. The patient's other maternal uncles and aunts have declined symptoms and genetic testing as well. The maternal grandmother developed heart failure and passed in her sixties and the maternal grandfather is still alive and was recently diagnosed with heart failure. The patient's mother denied any cardiac disease on the patient's paternal side. The patient’s twin brother was born with cleft lip and palate but the mother reports his cardiac testing was normal. The patient's twin brother was still alive and was recently diagnosed with heart failure. The patient's maternal uncle was diagnosed with CDM and atrial fibrillation and underwent ICD placement at age 37. She had declined genetic testing which was normal. The patient had five older siblings, some of whom have had cardiac symptoms but have declined testing (Fig. 1).

Initial presentation
The patient was lost to follow up for one year until time of presentation. She was brought in by her mother after she noted increased lower extremity and abdominal swelling and had a positive home pregnancy test. The patient stated that she thought her last period was the previous July and stated that intercourse was consensual. She did not have any cardiac related symptoms upon presentation. Her physical exam was normal with cardiovascular exam reported as normal rate and rhythm without murmur or pulmonary findings. EKG showed normal sinus rhythm. A bedside ultrasound dated the pregnancy at 37 weeks and 6 days. Her prescribed medications were enalapril 5 mg twice daily, furosemide 20 mg daily, aspirin 81 mg daily, spironolactone 25 mg twice daily, metoprolol 25 mg 1/2 pill per day; however, the patient reported poor adherence to the regimen. Rapid follow up was arranged and the patient was instructed to discontinue the enalapril and the spironolactone.

The patient presented to the Maternal Fetal Medicine (MFM) Clinic two days later. A maternal echocardiogram revealed increased LVEDD, ventricular septal defect, and severely decreased LVEF of approximately 20% as compared to 42% from one year prior. (Table 1).

Labor presentation
Three days later, the patient presented in active labor. Her initial cervical examination was 5 cm dilation/80% effacement/ 0 station and she was contracting every 2–3 min. Fetal heart tracing was Category 1. She reported shortness of breath with contractions only and denied any chest pain or palpitations. Physical exam was normal and EKG showed normal sinus rhythm. All vital signs were within normal limits.

MFM recommendations included close monitoring of fluid status with administration of Lasix if fluid overload was noted, maintenance of normal heart rate to allow for diastolic filling, epidural analgesia administration to alleviate patient pain, and assisted second stage delivery with vacuum or forceps as clinically indicated. They also recommended slow administration of epidural analgesia to minimize the risk of sympathetic blockade and acute drop in systemic venous return.

Delivery
The patient had a spontaneous vaginal delivery three hours later of a male infant weighing 3275 g, with APGAR scores of 8 and 9 at 5 and 10 min, respectively. The second stage of labor lasted 20 min. Delivery was complicated by postpartum hemorrhage caused by deep second degree perineal laceration and atonic uterus. Laceration repair and uterine massage were conducted. Postpartum oxytocin 10U, misoprostol 1000mcg rectally, carboprost 0.2 mg IV, and tranexamic acid 1 g IV were each administered once following institutional postpartum hemorrhage protocols. Total estimated blood loss was 1474 cc. Thoracotomy exam was conducted and uterus was noted to be firm and laceration hemostatic.

Postpartum
The postpartum course was complicated by acute blood loss anemia. Starting hemoglobin was 10.4 mg/dL and hemoglobin on postpartum day one was 8.1 mg/dL (Table 2). Pt reported shortness of breath with ambulation so pediatric cardiology recommendations were for transfusion of one unit packed red blood cells along with 10 mg furosemide. The patient’s intake and output were closely monitored to achieve as close to net neutral as possible. Post transfusion hemoglobin was 8.8 mg/dL and the patient reported resolution of symptoms. The patient
was counseled on breastfeeding but declined, deciding to exclusively formula feed her infant.

The patient was restarted on her prior medication regimen on postpartum day one as well as prophylactic subcutaneous heparin. On postpartum day two, the patient was fitted for a Zoll LifeVest (LifeVest®, ZOLL, Pittsburgh, PA, USA) wearable cardiac defibrillator (WCD). By postpartum day three, the patient was meeting all milestones and was discharged home. She received Depo-Provera for contraception prior to discharge.

At one month postpartum, the patient had an echocardiogram which showed severely dilated left ventricle with insignificant change from time of delivery and moderately to severely decreased ejection fraction, which was noted to be slightly improved from the time of delivery. The patient still had her WCD on and reported no symptoms and was meeting all postpartum milestones. She received a Paragard intrauterine device (ParaGard; Teva Pharmaceutical Industries Ltd., Sellersville, PA, USA) for long-acting reversible contraception and was
### Table 1  Patient's Echocardiogram Values From Time of Diagnosis to Presentation

| Age (years) | LV EF (%) | LV EDD (cm) | Z-score |
|-------------|-----------|-------------|---------|
| 15 months   | 3.6       |             |         |
| 18 months   | 8.6       |             |         |
| 2           | 45        | 3.5         | 1.7     |
| 2           | 46        | 3.6         | 1.5     |
| 3           | 55        | 3.7         | 1.6     |
| 4           | 51        | 4.1         | 1.8     |
| 5           | 44        | 4.1         | 1.5     |
| 6           | 55        | 4.5         | 2.1     |
| 7           | 52        | 5.0         | 2.0     |
| 7           | 43        | 4.4         | 0.5     |
| 8           | 45        | 4.8         | 1.2     |
| 8           | 50        | 5.3         | 2.1     |
| 9           | 48        | 5.3         | 1.9     |
| 10          | 54        | 5.6         | 1.9     |
| 11          | 54        | 6.4         | 2.3     |
| 13          | 42        | 6.3         | 0.9     |
| 14: Three days prior to delivery | “Severely decreased, (EF likely high 20-low 30 s)” | 6.5 | 1.9 |
| 14: 1 month postpartum | Moderately to Severely decreased, < 30% | 6.9 | |
| 14: 4 months postpartum | Moderately to Severely decreased | 6.8 | |

Patient's echocardiogram values since time of diagnosis

* Indicates measurements listed in clinician documentation

** Echo report states LVEF is slightly improved when compared with immediate prior study

*** Unchanged from the study from 1 month postpartum

### Table 2  Pre-Delivery and Post-Delivery Clinical Data

|                  | Pre-Delivery | On Admission | Postpartum Day 1 | Postpartum Day 2 | Postpartum Day 3 |
|------------------|--------------|--------------|------------------|------------------|------------------|
| **Vital Signs**  |              |              |                  |                  |                  |
| Systolic Blood Pressure | 147         | 128          | 123              | 101              | 109              |
| Diastolic Blood Pressure | 83          | 70           | 81               | 64               | 69               |
| Heart Rate       | 101          | 90           | 93               | 110              | 106              |
| **Tests**        |              |              |                  |                  |                  |
| EKG              | Normal Sinus Rhythm | Normal Sinus Rhythm | No Abnormal Telemetry Events Recorded |                  |                  |
| COVID PCR        | Negative     |              |                  |                  |                  |
| Group B Streptococcus | Positive   |              |                  |                  |                  |
| Urine Drug Screen| Negative     |              |                  |                  |                  |
| **Lab Values**   |              |              |                  |                  |                  |
| WBC (K/µL)       | 4.9          | 5.0          | 7.5              | 6.2              | 8.3              |
| Hemoglobin (g/dL)| 10.5         | 10.4         | 8.1              | 8.2              | 8.8              |
| Hematocrit (%)   | 33.3         | 33.0         | 25.3             | 26.1             | 27.9             |
| Platelets (K/µL)| 163          | 178          | 165              | 149              | 162              |
dispositioned to further follow up and management with pediatric cardiology.

At four months postpartum, the patient had follow-up with pediatric cardiology and was still asymptomatic and able to walk several blocks without symptoms. She was designated as New York Heart Association Class II Heart Failure. Repeat echocardiogram showed persistently severely dilated left ventricle with no further change from prior study and moderately to severely decreased ejection fraction with no change from one month postpartum. She was recommended to continue with WCD use with consideration for permanent ICD placement based on symptomatology and echocardiographic findings.

**Neonatal care**
The patient delivered a male infant with normal genitalia. A postnatal echocardiogram identified normal four chamber intracardiac anatomy with normal atrioventricular and ventriculoarterial relationships.

**Discussion and conclusions**
Our patient met criteria for FDC, defined as idiopathic dilated cardiomyopathy in two or more family members [7]. This condition is distinguished from peripartum cardiomyopathy (PPCM) which has various definitions but all of which mention the absence of pre-existing heart disease as a criterion [6, 8]. However, Van Spaendonck et al. raise the possibility that a subset of PPCM may be part of the spectrum of FDC with initial presentation in the postpartum period [9]. They demonstrated cases of PPCM in FDC families as well as previously undiagnosed FDC in families with patients with PPCM that did not recover fully. This theory has been substantiated at the genetic level by Ware et al. who showed that 16% of PPCM patients carry FDC-associated gene variants often in the sarcomere protein titin [10]. For previously asymptomatic FDC patients, the hemodynamic challenges of pregnancy may represent the inciting factor that tips a patient into overt disease [9]. Further family history screening and genetic counseling for those PPCM patients that do not recover fully may prove beneficial in early detection of disease in asymptomatic family members. This approach proved successful in prior case reports in the literature [11, 12].

FDC inheritance typically follows an autosomal dominant pattern and often involves cytoskeleton or sarcomere proteins, although a wide variety of genes and inheritance patterns have been described [13]. The American College of Cardiology recommends clinical screening and cascade genetic testing for asymptomatic relatives of index patients as it may improve outcomes and decrease hospitalization and death due to heart failure [14]. If familial mutations are known, prenatal or preimplantation genetic screening can be considered; however, these are not routinely performed due to variable expressivity and cost barriers, among others [6]. Patient autonomy is also a primary consideration in this discussion. Our patient’s mother indicated that some of her siblings and some of the index’s patient’s siblings have had cardiac symptoms but have declined testing, stating that they do not want the intrusion of a medical diagnosis on their lives. While patient wishes should be respected, asymptomatic family members should be thoroughly counseled to notify health care providers of this strong family history as well as cardiac warning signs and symptoms, especially if considering pregnancy.

Known FDC does allow providers an advantage in that proper care can ideally be delivered from the preconception period onward. This was not applicable in our case due to late onset of prenatal care. Fortunately, despite sub-optimal prenatal care and follow up, our patient successfully delivered a healthy child with minimal peripartum or postpartum complications. This circumstance provides an opportunity to highlight the importance of contraception counseling upon the onset of menses, more likely to be encountered by pediatric providers for these patients. The American Association of Pediatrics recommends that adolescent contraceptive needs be addressed in the primary care setting [15]. However, the proportion of providers who discuss contraception with patients is varying [16].

For an adolescent to seek out preconception counseling is unlikely as in our case, but if applicable, FDC patients would benefit from this counseling [17]. If pregnancy is found in the first or second trimester, appropriate care would involve a discussion with the patient of the risks and benefits of continuation of the pregnancy based on her clinical status and her management options. Regardless of decision, at initial diagnosis of pregnancy, medical reconciliation is necessary. In our case, the patient was not compliant with her regimen of enalapril, furosemide, aspirin, spironolactone, and metoprolol, a potential explanation for the lack of observed adverse effects. Of these medication classes, ACEI are contraindicated due to risks of teratogenicity, fetal renal failure, and neonatal death and spironolactone is not advised due to anti-androgen activity leading to feminization of males in limited animal studies [6]. Diuretics and selective beta blockers such as metoprolol are noted to be relatively safe and can be considered after weighing maternal and neonatal risks and benefits [18]. There are no specific imaging guidelines but a baseline echocardiogram and repeat scan each trimester is a reasonable approach to evaluate adaptation to pregnancy hemodynamics and to assist in delivery planning. Formation of a multi-disciplinary care delivery plan between the primary OB-GYN,
maternal-fetal medicine, cardiology, anesthesia, and nursing is also beneficial in mitigating risk and optimizing outcomes [6, 19].

Although our patient’s echocardiogram findings severely deteriorated from pre-pregnancy values, from the limited history gathered, the patient maintained New York Heart Association Class I or II functional status throughout her antenatal course and had minimal adverse outcomes through delivery and postpartum. A systematic review of various types of inherited cardiomyopathy in pregnancy states that asymptomatic and mildly symptomatic patients have a low risk of adverse events, although long-term studies are noted to be limited [3, 6, 20]. It is possible that since the patient was young, she was better able to compensate against her worsening cardiac function as compared to an older woman in a similar clinical setting. This hypothesis is limited by the patient’s recall bias of her symptomatology and the heterogeneity of clinical manifestations of FDC [21].

This case presented is the first reported case of placement of a WCD in a pediatric patient in the postpartum setting. Due to the elevated risk of ventricular arrhythmia in the postpartum setting, pediatric cardiology recommendations included application of a WCD with re-evaluation postpartum. Duncker et al. demonstrated that adult women with PPCM with severely reduced ejection fraction carry an elevated risk of ventricular tachyarrhythmias that may lead to sudden cardiac death [22]. A retrospective cohort study of WCDs in pediatric patients showed that WCDs were safe and effective in treating these arrhythmias and that compliance was good based on wear time per day [23]. The patient’s mother had previously used a LifeVest before placement of her ICD and was able to assist her daughter in instruction and care, which was greatly beneficial.

Pregnancy in FDC can hold serious morbidity and mortality and ideally requires preconception counseling and close management of prenatal care. Multi-disciplinary management with obstetricians, cardiologists, and anesthesiologists is crucial in the delivery and postpartum setting to achieve optimal outcomes. Follow up care for patients is crucial to monitor need for ICD placement and conversations with family members on the importance of screening and possible genetic testing.

Abbreviations
CDM: Cardiomyopathy; FDC: Familial dilated cardiomyopathy; LVEF: Left ventricular ejection fraction; ACEI: Angiotensin converting enzyme inhibitors; LVEDD: Left ventricular end diastolic diameter; ICD: Implantable cardioverter defibrillator; MFM: Maternal fetal medicine; WCD: Wearable cardiac defibrillator; PPCM: Peripartum cardiomyopathy.

Acknowledgements
The authors would like to thank the patient and family as well as all the physicians, nurses, and hospital staff that participated in the patient’s care.

Authors’ contributions
Both JG and JJ were part of patient care during hospital admission and were contributors in writing of the manuscript. Both authors read and approved the final manuscript.

Funding
There is no specific funding for this work. This research was performed as part of employment at Detroit Medical Center/Hutzel Women’s Hospital.

Availability of data and materials
The data gathered in this case report were obtained upon review of the patient’s medical record and thus are not publicly available but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
No manuscript preparation assistance was used in the creation of this report. Wayne State University IRB approval was waived as this case report did not meet criteria for Human Participant Research.

Consent for publication
Written consent has been obtained from the patient and patient’s mother for the publication of this case report. A copy of this consent form is available for review by the Editor.

Competing interests
The authors declare that they do not have any competing or financial interests.

Received: 24 November 2020 Accepted: 26 January 2022 Published online: 01 February 2022

References
1. Roos-Hesselink JW, Ruys TP, Stein JJ, Thilen U, Webb GD, Niwa K, Kaemmerer H, Baumgartner H, Budts W, Maggioni AP, Tavazzi L, Tahta N, Johnson MR, Hall R. Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J. 2013;34(9):657–65.
2. Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC, Kells CM, Bergin ML, Kiess MC, Marcotte F, Taylor DA, Gordon EP, Spears JC, Tam JW, Arninkwah KS, Smallhorn JF, Farine D, Sorensen S, Cardiac Disease in Pregnancy (CAPREG) Investigators. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001;104:S15–21.
3. Grewal J, Siu SC, Ross HJ, Mason J, Balint OH, Sermer M, Colman JM, Silver-sides CK. Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol. 2009;55:45–52.
4. Gevaert S, De Pauw M, Tromp F, Ascoop A-K, Roelens K, De Backer J. Treatment of pre-existing cardiomyopathy during pregnancy. Acta Cardiol. 2014;69(2):193–6. https://doi.org/10.1080/AC.69.2.2013.272.
5. Cunningham FG, Byrne JJ, Nelson DB. Peripartum Cardiomyopathy. Obstet Gynecol. 2019;133(1):167–79. https://doi.org/10.1097/AOG.00000000000003011.
6. Krul SP, van der Smagt JJ, van den Berg MP, Sollie KM, Pieper PG, van Spaandonck-Zwarts KY. Systematic review of pregnancy in women with inherited cardiomyopathies. Eur J Heart Fail. 2011;13(6):584–94. https://doi.org/10.1093/eurjhf/hfr040.
7. Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol. 2005;45:969–81.
8. Slivka K, Bohm M. Incidence and prevalence of pregnancy-related heart disease. Cardiovasc Res. 2014;104(1):534–60. https://doi.org/10.1093/cvr/cvu012.
9. van Spaandonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010;121(20):2169–75. https://doi.org/10.1161/CIRCULATIONAHA.109.929646.
10. Ware JS, Li J, Mazaika E, et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med. 2016;374(3):233–41. https://doi.org/10.1056/NEJMoa1505517.
11. Fett JD, Sundstrom BJ, Etta King M, Ansari AA. Mother-daughter peripartum cardiomyopathy. Int J Cardiol. 2002;86(2–3):331–2. https://doi.org/10.1016/S0167-5273(02)00357-1.
12. Tibazarwa K, Sliwa K, Wonkam A, Mayosi BM. Peripartum cardiomyopathy and familial dilated Cardiomyopathy: a tale of two cases. Cardiovasc J Afr. 2013;24(5):e4–7. https://doi.org/10.5830/CVJA-2013-027.
13. Taylor MR, Camiel E, Mestroni L. Cardiomyopathy, familial dilated. Orphanet J Rare Dis. 2006;1:27.
14. Hershberger RE, Givertz MM, Ho CY, et al. Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. J Card Fail. 2018;24(5):281–302. https://doi.org/10.1016/j.cardfail.2018.03.004.
15. Contraception for adolescents. Pediatrics. 2014;134(4):e1244–56.
16. Swanson KJ, Gossett DR, Fournier M. Pediatricians’ beliefs and prescribing patterns of adolescent contraception: a provider survey. J Pediatr Adolesc Gynecol. 2013;26(6):340–5.
17. Liu Y, Bock MJ, Gold JA. The importance of preconception and prenatal genetic evaluation in heart transplant individuals and fetal and postnatal cardiac monitoring in their offspring. Cardiol Young. 2018;28:1356–8.
18. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol. 2019;133(1):e26–50.
19. Schuler PK, Herhey A, Wade A, et al. Pregnancy outcome and management of women with an implantable cardioverter defibrillator: a single centre experience. Europace. 2012;14(12):1740–5. https://doi.org/10.1093/europace/eus172.
20. Bernstein PS, Magriples U. Cardiomyopathy in pregnancy: a retrospective study. Am J Perinatol. 2001;18:163–8.
21. de Gonzalo-Calvo D, Quezada M, Campuzano O, et al. Familial dilated cardiomyopathy: A multidisciplinary entity, from basic screening to novel circulating biomarkers. Int J Cardiol. 2017;228:870–80. https://doi.org/10.1016/j.ijcard.2016.11.045.
22. Duncker D, Haghikia A, König T, et al. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail. 2014;16(12):1331–6. https://doi.org/10.1002/ejhf.188.
23. Spar DS, Bianco NR, Knlans TK, Czosek RJ, Anderson JB. The US Experience of the Wearable Cardioverter-Defibrillator in Pediatric Patients. Circ Arrhythm Electrophysiol. 2018;11(7): e006163. https://doi.org/10.1161/CIRCEP.117.006163.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.